Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

690
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
690
Drug Regulation01:25

Drug Regulation

1.8K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.3K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

838
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
838
Pharmacovigilance01:19

Pharmacovigilance

974
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
974

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

One-step assembly of multi-layered structures with orthogonally oriented stripe-like patterns on the surface of a capillary tube.

Physical chemistry chemical physics : PCCP·2017
Same author

The role of elevated serum procalcitonin in neuroendocrine neoplasms of digestive system.

Clinical biochemistry·2017
Same author

Activation of sirtuin 1 by catalpol-induced down-regulation of microRNA-132 attenuates endoplasmic reticulum stress in colitis.

Pharmacological research·2017
Same author

Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by <i>Ex Vivo</i> PI3K-δ Inhibition.

Cancer research·2017
Same author

Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics.

Proceedings of the National Academy of Sciences of the United States of America·2017
Same author

Protective effects of dioscin against cisplatin-induced nephrotoxicity via the microRNA-34a/sirtuin 1 signalling pathway.

British journal of pharmacology·2017

Related Experiment Video

Updated: Sep 2, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

2.8K

[FDA Premarket Pathways for Combination Products].

Yuan Lin1

  • 1Potrero Medical, INC., Hayward, California, USA, 94545.

Zhongguo Yi Liao Qi Xie Za Zhi = Chinese Journal of Medical Instrumentation
|August 5, 2022
PubMed
Summary
This summary is machine-generated.

This paper clarifies the U.S. Food and Drug Administration's (FDA) guidance for combination products. It offers strategies for Chinese manufacturers navigating pre-market approval in the United States.

Keywords:
FDAcombination productsdesignationpremarket pathwaysupervision

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K

Related Experiment Videos

Last Updated: Sep 2, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

2.8K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K

Area of Science:

  • Regulatory Science
  • Pharmaceutical Science
  • Medical Device Science

Background:

  • Combination products, integrating drug, device, or biological elements, present unique development and regulatory hurdles.
  • Existing regulatory frameworks for individual products do not fully address the complexities of combination products.
  • Navigating the U.S. market requires understanding specific FDA policies and pathways.

Purpose of the Study:

  • To elucidate the U.S. Food and Drug Administration (FDA) guidance on combination products.
  • To analyze current trends and strategies for the pre-market approval of combination products.
  • To provide actionable insights for Chinese researchers and manufacturers entering the U.S. market.

Main Methods:

  • Interpretation of existing FDA policies and regulations pertaining to combination products.
  • Analysis of recent trends in combination product applications and approvals.
  • Synthesis of strategic approaches for successful pre-market submissions.

Main Results:

  • Detailed explanation of FDA's regulatory framework for combination products.
  • Identification of key challenges and opportunities in the pre-market review process.
  • Outline of strategic considerations for product development and submission.

Conclusions:

  • Understanding FDA's specific guidance is crucial for combination product development.
  • Proactive strategic planning can mitigate regulatory challenges for market entry.
  • This guidance aims to facilitate U.S. market access for Chinese combination product innovators.